CRISPR Medicine News, 8 April 2020 - CRISPR Medicine

Happy Easter! And thank You for reading

We have a bunch of good news for you!

  • Find it hard to keep track of all the recent news about CRISPR clinical trials? Help is here! We have compiled a comprehensive list of all the gene-editing clinical studies currently registered in the US, China and Europe. Have a look - it's a growing list, and we will keep it updated.
  • And we have posted a companion piece for our CRISPR clinical trials status overview 2020. Read about the trends across all the trials, the sort of treatments and diseases, the front-runners in CRISPR gene editing are focusing on.

And while on the topic of clinical trials...

Other good reads

And we are growing!

We are happy to announce two more beautiful additions who will bring more and even better content to CRISPR Medicine News (c;

Science Writer Karen O'Hanlon Cohrt hails from Ireland where she obtained an Honours Bachelor Degree in Biological Sciences and a PhD in Biotechnology. She has a strong and broad research background, developed through a decade of work in various academic and startup labs in Ireland and Denmark. Karen is passionate about learning, asking questions and sharing knowledge with others - she will bring You loads of exciting stories that are bound to stimulate interesting discussions.

Scientific Assistant Iro Efthymia Pappa is a Greek national studying Engineering in Biotechnology at the Technical University of Denmark. She has experience working with multidisciplinary projects, speaks three languages and has worked for several years in her nutrition practice before coming to Denmark. She loves having a front seat as she is helping out researching for the CRISPR Medicine Blog on the revolutionary changes in disease therapy.

You can see who we are and read more in the About section.

Thank You for now - have a great Easter.

And if you have questions or suggestions, you can directly reach us at We love hearing from readers!

(c; Rasmus


You can follow the blog on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up yourself here.